Environmental pollutants, including ambient particulate matter (PM), increase respiratory morbidity. Studies of model PM particles, including residual oil fly ash and freshly generated diesel exhaust particles, have demonstrated that PM affects inflammatory airway responses. Neither of these particles completely represents ambient PM, and therefore questions remain about ambient particulates. We hypothesized that ambient PM of different size fractions collected from an urban environment (New York City air), would activate primary culture human bronchial epithelial cells (HBECs). Because of the importance of granulocyte-macrophage colony-stimulating factor (GM-CSF) on inflammatory and immunomodulatory processes, we focused our studies on this cytokine. We demonstrated that the smallest size fraction (ultrafine/fine; < 0.18 micro m) of ambient PM (11 micro g/cm(2)), upregulated GM-CSF production (2-fold increase). The absence of effect of carbon particles of similar size, and the day-to-day variation in response, suggested that the chemical composition, but not the particle itself, was necessary for GM-CSF induction. Activation of the extracellular signal-regulated kinase and the p38 mitogen-activated protein kinase was associated with, and necessary for, GM-CSF release. These studies serve to corroborate and extend those on model particles. Moreover, they emphasize the role of the smallest size ambient particles in airway epithelial cell responses.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1165/rcmb.2001-0005OC | DOI Listing |
AAPS J
January 2025
Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liège, 4000, Liège, Belgium.
In addition to the known therapeutic indications for cannabidiol, its administration by inhalation appears to be of great interest. Indeed, there is evidence of cannabidiol's efficacy in several physiological pathways, suggesting its potential for a wide range of applications for both local and systemic pulmonary administration like cancers. Significant advances in pulmonary drug delivery have led to innovative strategies to address the challenges of increasing the respirable fraction of drugs and standardizing inhalable products.
View Article and Find Full Text PDFJ Appl Clin Med Phys
January 2025
Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, Illinois, USA.
Background: Various methods exist to correct for intrafraction motion (IFM) of the prostate during radiotherapy. We sought to characterize setup corrections in our practice informed by the TrueBeam Advanced imaging package, and analyze factors associated with IFM.
Methods: 132 men received radiation therapy for prostate cancer with a volumetric modulated arc therapy technique.
Front Cardiovasc Med
January 2025
Department of Cardiovascular Medicine, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Background: Atrial fibrillation (AF) is a prevalent cardiac arrhythmia, with ventricular rate control being a critical therapeutic target. However, the optimal range for ventricular rate control remains unclear. Additionally, the relationship between different levels of ventricular rate control and cardiac remodeling in patients with atrial fibrillation remains unclear.
View Article and Find Full Text PDFEndocr Oncol
January 2024
Department of Oncology, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
Summary: Craniopharyngiomas (CPs) are rare brain epithelial tumours arising in the suprasellar region, infiltrating adjacent areas causing visual loss, panhypopituitarism, cognitive deficits and morbid obesity. Papillary CPs (PCPs) harbour in 94% BRAF mutation cases. Two patients with PCP and BRAF V600E mutations but with different tumour status were treated with BRAF and MEK inhibitors.
View Article and Find Full Text PDFESC Heart Fail
January 2025
School of Clinical Medicine, Fujian Medical University, Department of Cardiology, Affiliated Hospital of Putian University, Putian, China.
Purpose: Vericiguat, a soluble guanylate cyclase (sGC) stimulator, has been demonstrated effective in improving prognosis of patients with heart failure with reduced ejection fraction. However, there are limited data concerning the effect of vericiguat in patients with doxorubicin (DOX)-induced cardiomyopathy (DIC). In this study, we investigated the effects of vericiguat on cardiac structure and function in rats with DIC as well as their potential mechanisms of action.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!